The FDA must thoroughly review alarming new data showing mifepristone complications may be 22 times higher than previously reported. Insurance claims from over 865,000 prescriptions reveal nearly 11% of women experience potentially life-threatening complications within 45 days. Current safety restrictions exist for good reason and protect women from a drug that poses serious risks.